Phase 3 Trial Targets Chronic Hepatitis Delta Suppression

This site is intended for healthcare professionals

Dual Antiviral Regimen Suppresses Chronic Hepatitis Delta in Phase 3

Author:
blood sample tube for hepatitis D virus test analysis

Key Summary:

  • Monthly elebsiran plus tobevibart achieved dual viral suppression and ALT normalization in 44% of patients.
  • Overall, 79% of treated adults reached undetectable hepatitis delta virus RNA at 48 weeks without dropouts.
  • Viral suppression remained robust in compensated cirrhosis, with 85% achieving undetectable RNA levels.

MONTHLY subcutaneous combination therapy achieves undetectable viral RNA and liver enzyme normalization in chronic hepatitis delta. Results from the randomized, open-label Phase 3 ECLIPSE 1 trial indicate that pairing the small interfering RNA elebsiran with the monoclonal antibody tobevibart produces substantial virologic and biochemical responses over 48 weeks. Because coinfection with hepatitis delta virus accelerates progression to cirrhosis and hepatic decompensation, durable viral suppression remains a primary therapeutic goal in hepatology practice.

Efficacy in Chronic Hepatitis Delta

The multicenter investigation enrolled 124 adults with chronic hepatitis delta receiving background nucleos(t)ide analog therapy, approximately 55% of whom had compensated cirrhosis at baseline. Investigators randomized participants in a 2:1 ratio to receive subcutaneous elebsiran 200 mg plus tobevibart 300 mg every four weeks or delayed treatment initiated at Week 12. At Week 48, 44% of patients in the immediate-treatment arm achieved the primary composite endpoint of undetectable hepatitis delta virus RNA alongside alanine aminotransferase normalization, compared with 0% in the delayed-treatment group at Week 12. All treated participants achieved a virologic response by Week 24, and 79% reached undetectable viral RNA by Week 48, including 85% of individuals with compensated cirrhosis and 73% of those without cirrhosis. Additionally, hepatitis B surface antigen levels declined below 10 IU/mL in 95% of treated patients.

Tolerability and Clinical Implications

Safety outcomes across the 48-week treatment window demonstrated favorable tolerability and high adherence. Every participant assigned to immediate combination therapy completed the full 48-week regimen without treatment interruptions or discontinuations. Most treatment-related adverse events were mild to moderate and transient, consisting primarily of flu-like symptoms following the initial dose that resolved within 24 to 48 hours. Investigators documented a single grade 3 treatment-related adverse event involving decreased neutrophil count, which resolved within 15 days. For physicians managing chronic hepatitis delta, a once-monthly subcutaneous regimen capable of suppressing viral replication and reducing hepatitis B surface antigen burden offers a promising clinical approach pending confirmatory Phase 3 readouts.

Reference

Reau N et al. Primary endpoint results of ECLIPSE 1: a randomized open-label phase 3 study evaluating efficacy and safety of elebsiran and tobevibart for chronic hepatitis delta. Presented at: The Liver Meeting; November 5–9, 2026; Denver, CO.

kitsawet on adobe stock

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Rate this content's potential impact on patient outcomes

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this content.